announces the completion of the exercise of the 16th stock acquisition rights. For the monthly exercise status, 2,100 rights were exercised against 210,000 shares issued, representing 12.4% of total issued rights. Total issued shares: 8,383,200; unexercised rights: 0. As of August 27.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Klinglea Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4884-20260827-01.pdf","jir_short_summary":" announces the completion of the exercise of the 16th stock acquisition rights. For the monthly exercise status, 2,100 rights were exercised against 210,000 shares issued, representing 12.4% of total issued rights. Total issued shares: 8,383,200; unexercised rights: 0. As of August 27.","jir_summary":"### Overview\nToday, we announce the completion of all exercises of the 16th stock acquisition rights issued through third-party allotment with exercise price adjustment provisions. In the monthly exercise status, 2,100 rights were exercised against 210,000 allocated shares, with an exercise rate of 12.4% of the total issued rights. Unexercised shares stand at 0, and the total exercise ratio records 3.1%.\n\n### Impact going forward\nTotal issued shares are 8,383,200 (including 183 treasury shares). The completion of this exercise is expected to have a limited dilutive impact. All monthly exercise status for August 2026 has been completed, and we will continue to disclose stock option management status.","jir_financial_highlights":"Allocated shares: 210,000 shares (Allocated shares from the beginning of the month)\nExercised stock acquisition rights: 2,100 rights (Number of stock acquisition rights exercised since the beginning of the month)\nTotal issued stock acquisition rights: 17,000 rights (Proportion 12.4%)\nIssued shares: 8,383,200 shares (As of July 30, 2026)\nUnexercised stock acquisition rights: 0 shares (As of now)\nExercise restriction exercise rate: 3.1% (Based on Listing Regulations Article 434)","jir_category":"","jir_hashtags":"#KlingleaPharma, #StockAcquisitionRights, #StockOptions, #EquityPolicy","jir_key_figures":"Allocated shares: 210,000 shares\nTotal issuing stock acquisition rights: 17,000 rights\nNumber of exercised stock acquisition rights: 2,100 rights","jir_meta_title":"\u3010KlingleaPharma\u3011Exercise Completion of Third-Party Allotment Stock Acquisition Rights and Monthly Status | August 2026","jir_meta_description":"KlingleaPharma announces the completion of all exercises of the 16th stock acquisition rights issued via third-party allotment. Monthly status shows 2,100 rights exercised out of 210,000 allocated shares. Issued shares: 8,383,200; unexercised: 0. Exercise rate: 3.1%.","jir_og_title":"KlingleaPharma | Exercise Completion of Stock Acquisition Rights","jir_og_description":"Announcement of exercise completion and monthly status for stock acquisition rights. Out of 17,000 total, 2,100 rights exercised; issued shares 8,383,200; unexercised 0.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-107737","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n